Posts

EPO pharma case law trends 2025: Antibodies and biologics

Takeda v Roche: "Is it plausible? Is it true?"

SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19)

Roche shields itself from a UK Arrow: Pfizer v Roche

Fordham 27 (Report 9): Biologics and Biosimilars

Shall we dance? Regulatory approval, trade secrets and the transatlantic biosimilars patent wars

The Evolution of U.S. Law and the Bio-Pharmaceutical Industry